Business Segments · Research and development expenses
Cardiovascular — Research and development expenses
Boston Scientific Cardiovascular — Research and development expenses decreased by 8.5% to $343M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.2%, from $283M to $343M. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Research and development expenses shows an upward trend with a 18.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026May 1, 2026
How to read this metric
Consistent or increasing investment is generally required to maintain a competitive edge in medical technology.
Detailed definition
Captures the investment in innovation, clinical trials, and product development specifically for the Cardiovascular segm...
Peer comparison
Standard R&D reporting for technology-driven healthcare companies.
Metric ID:
bsx_segment_cardiovascular_research_and_development_expensesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $195.5M | $195.5M | $195.5M | $195.5M | $214.75M | $214.75M | $214.75M | $214.75M | $228M | $231M | $244M | $276M | $283M | $315M | $337M | $375M | $343M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +9.8% | +0.0% | +0.0% | +0.0% | +6.2% | +1.3% | +5.6% | +13.1% | +2.5% | +11.3% | +7.0% | +11.3% | -8.5% |
| YoY Change | — | — | — | — | +9.8% | +9.8% | +9.8% | +9.8% | +6.2% | +7.6% | +13.6% | +28.5% | +24.1% | +36.4% | +38.1% | +35.9% | +21.2% |
Range$195.5M – $375M
CAGR+15.1%
Avg YoY Growth+19.3%
Median YoY Growth+13.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — research and development expenses?
- Boston Scientific (BSX) reported cardiovascular — research and development expenses of $343M in Q1 2026.
- How has Boston Scientific's cardiovascular — research and development expenses changed year-over-year?
- Boston Scientific's cardiovascular — research and development expenses increased by 21.2% year-over-year, from $283M to $343M.
- What is the long-term trend for Boston Scientific's cardiovascular — research and development expenses?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — research and development expenses has grown at a 18.8% compound annual growth rate (CAGR), from $782M to $1.31B.
- What does cardiovascular — research and development expenses mean?
- The amount spent on research and development for cardiovascular products.